Novo Nordisk Faces Dual Challenges Amid Strategic Shifts

The Danish pharmaceutical giant Novo Nordisk is navigating a complex period marked by operational restructuring and legal scrutiny. As the company advances the U.S. launch of its oral Wegovy tablet, it confronts new job cuts and a significant antitrust lawsuit related to its diabetes portfolio.

A new legal challenge emerged last Friday when a class-action lawsuit was filed against Novo Nordisk in a U.S. federal court in New York. The complaint alleges anticompetitive practices concerning the diabetes drug Victoza.

Plaintiffs accuse Novo Nordisk and Teva Pharmaceuticals of engaging in a “pay-for-delay” agreement. This alleged deal purportedly pushed back the market entry of more affordable generic versions until Read more...